Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system

被引:1549
作者
Mehta, Puja K. [1 ]
Griendling, Kathy K. [1 ]
机构
[1] Emory Univ, Div Cardiol, Dept Med, Atlanta, GA 30322 USA
来源
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY | 2007年 / 292卷 / 01期
关键词
vascular smooth muscle; NAD(P) H oxidase; tyrosine and nontyrosine receptor kinases; endothelial dysfunction; vascular disease;
D O I
10.1152/ajpcell.00287.2006
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The renin-angiotensin system is a central component of the physiological and pathological responses of cardiovascular system. Its primary effector hormone, angiotensin II (ANG II), not only mediates immediate physiological effects of vasoconstriction and blood pressure regulation, but is also implicated in inflammation, endothelial dysfunction, atherosclerosis, hypertension, and congestive heart failure. The myriad effects of ANG II depend on time (acute vs. chronic) and on the cells/tissues upon which it acts. In addition to inducing G protein- and non-G protein- related signaling pathways, ANG II, via AT(1) receptors, carries out its functions via MAP kinases (ERK 1/2, JNK, p38MAPK), receptor tyrosine kinases [PDGF, EGFR, insulin receptor], and nonreceptor tyrosine kinases [Src, JAK/ STAT, focal adhesion kinase (FAK)]. AT(1)R-mediated NAD(P)H oxidase activation leads to generation of reactive oxygen species, widely implicated in vascular inflammation and fibrosis. ANG II also promotes the association of scaffolding proteins, such as paxillin, talin, and p130Cas, leading to focal adhesion and extracellular matrix formation. These signaling cascades lead to contraction, smooth muscle cell growth, hypertrophy, and cell migration, events that contribute to normal vascular function, and to disease progression. This review focuses on the structure and function of AT(1) receptors and the major signaling mechanisms by which angiotensin influences cardiovascular physiology and pathology.
引用
收藏
页码:C82 / C97
页数:16
相关论文
共 224 条
[51]  
GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450
[52]   TISSUE-SPECIFIC EXPRESSION OF TYPE-1 ANGIOTENSIN-II RECEPTOR SUBTYPES - AN IN-SITU HYBRIDIZATION STUDY [J].
GASC, JM ;
SHANMUGAM, S ;
SIBONY, M ;
CORVOL, P .
HYPERTENSION, 1994, 24 (05) :531-537
[53]   ANGIOTENSIN-II INDUCES HYPERTROPHY, NOT HYPERPLASIA, OF CULTURED RAT AORTIC SMOOTH-MUSCLE CELLS [J].
GEISTERFER, AAT ;
PEACH, MJ ;
OWENS, GK .
CIRCULATION RESEARCH, 1988, 62 (04) :749-756
[54]   Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages:: Implications for atherogenesis [J].
Gerdes, N ;
Sukhova, GK ;
Libby, P ;
Reynolds, RS ;
Young, JL ;
Schönbeck, U .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 195 (02) :245-257
[55]   Oxidative stress and diabetic vascular complications [J].
Giugliano, D ;
Ceriello, A ;
Paolisso, G .
DIABETES CARE, 1996, 19 (03) :257-267
[56]   Interactions between the sympathetic nervous system and the RAAS in heart failure [J].
Goldsmith S.R. .
Current Heart Failure Reports, 2004, 1 (2) :45-50
[57]   Specific regulation of RGS2 messenger RNA by angiotensin II in cultured vascular smooth muscle cells [J].
Grant, SL ;
Lasseègue, B ;
Griendling, KK ;
Ushio-Fukai, M ;
Lyons, PR ;
Alexander, RW .
MOLECULAR PHARMACOLOGY, 2000, 57 (03) :460-467
[58]   Caveolae and caveolins in the cardiovascular system [J].
Gratton, JP ;
Bernatchez, P ;
Sessa, WC .
CIRCULATION RESEARCH, 2004, 94 (11) :1408-1417
[59]   Modulation of insulin-stimulated degradation of human insulin receptor substrate-1 by serine 312 phosphorylation [J].
Greene, MW ;
Sakaue, H ;
Wang, LH ;
Alessi, DR ;
Roth, RA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (10) :8199-8211
[60]  
Griendling K K, 1994, Adv Pharmacol, V28, P269, DOI 10.1016/S1054-3589(08)60498-6